AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 8863301
Drug: Real low-level
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Real low-level laser treatment (4 x 6 J per treatment, 20 treatments total)
Trial: 2031770
Drug: 10 MU/m2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 MU/m2 of rIFN-alpha, I.M., twice a week for six months
Trial: 2031770
Drug: 7.5 MU/m2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7.5 MU/m2 of rIFN-alpha, I.M., twice a week for six months
Trial: 2031770
Drug: rIFN-alpha therapy
RxNorm normalized name: rIFN-alpha-2a
DrugBank: Interferon alfa-2a (DB00034)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rIFN-alpha therapy (both dosages)
Trial: 25239078
Drug: IFN-free therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IFN-free therapy (danoprevir/r 100/100mg, mericitabine 1000 mg, ribavirin 1000/1200 mg)
Trial: 25239078
Drug: Triple therapy
RxNorm normalized name: MigreLief Triple Therapy with Puracol Caplet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triple therapy (danoprevir/r plus PegIFN alfa-2a/ribavirin)
Trial: 25239078
Drug: Quad therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quad therapy (danoprevir/r, mericitabine, PegIFN alfa-2a/ribavirin)
Trial: 25239078
Drug: IFN-free therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IFN-free therapy
Trial: 25239078
Drug: Quad therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quad therapy (Quad 24)
Trial: 25239078
Drug: Quad therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quad therapy (Quad 48)
Trial: 25239078
Drug: Quad therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quad therapy (partial)
Trial: 25239078
Drug: Quad therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quad therapy (null 24)
Trial: 22351891
Drug: Treatment failure
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment failure
Trial: 16409455
Drug: Both preparations
RxNorm normalized name: cranberry preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both preparations of COC
Trial: 16129293
Drug: Removal of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Removal of lens epithelial cells (LECs) from the anterior capsule during cataract surgery
Trial: 12504937
Drug: Education, age
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Education, age at menarche, oral contraceptive use, smoking habits
Trial: 9507749
Drug: Ciprofloxacine 250
RxNorm normalized name: ciprofloxacin 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ciprofloxacine 250 mg every 12 hours for 14 days (n = 7)
Trial: 9507749
Drug: Trimethoprim 160
RxNorm normalized name: trimethoprim 160 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trimethoprim 160 mg and sulfamethoxazole 800 mg every 12 hours for 14 days (n = 6)
Trial: 7896975
Drug: Experimental group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Experimental group (exposed to a distinctive stimulus before each chemotherapy infusion)
Trial: 346617
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg diazepam per day
Trial: 23929924
Drug: Angiotensin II
RxNorm normalized name: Angiotensin II
DrugBank: Angiotensin II (DB11842)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Angiotensin II receptor blockers (losartan or telmisartan)
Trial: 19099641
Drug: CD34+ cell
RxNorm normalized name: CD34+ Cells
DrugBank: Autologous peripheral blood-derived CD34+ cells (DB16367)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CD34+ cell dose > 2 x 10^6/kg
Trial: 15684204
Drug: Outpatient care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Outpatient care with oral levofloxacin therapy
Trial: 15684204
Drug: Hospitalization with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hospitalization with sequential intravenous and oral levofloxacin therapy
Trial: 12850904
Drug: Fixed diazepam
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fixed diazepam tapering regime
Trial: 12850904
Drug: Symptom-triggered taper
RxNorm normalized name: Pamprin Multi-Symptom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Symptom-triggered taper method (diazepam only in response to withdrawal symptoms)
Trial: 10229153
Drug: Combined Low
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined Low Intensity Laser Therapy/Phototherapy (CLILT) (660-950 nm; 11 J/cm2; pulsed at 73 Hz)
Trial: 7156877
Drug: Instillation of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Instillation of 0.1 N HCl (2.5, 5, 10, and 15 ml volumes)
Trial: 28419747
Drug: 75 mg
RxNorm normalized name: talc 75 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 75 mg daprodustat
Trial: 28419747
Drug: 500 mg
RxNorm normalized name: bran 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 mg daprodustat
Trial: 26007314
Drug: High-dose ibuprofen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose ibuprofen (20-10-10 mg/kg/d) for 3 days
Trial: 26007314
Drug: Standard-dose ibuprofen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard-dose ibuprofen (10-5-5 mg/kg/d) for 3 days
Trial: 23339736
Drug: Initial maxillary
RxNorm normalized name: Artemisia capillaris leaf extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Initial maxillary expansion followed by U-bow activator therapy
Trial: 23274323
Drug: Campath 30
RxNorm normalized name: Campath 30 MG/ML Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Campath 30 mg + methylprednisolone 500 mg followed by TAC monotherapy (Group A)
Trial: 23274323
Drug: ATG 8
RxNorm normalized name: equine ATG
DrugBank: Antilymphocyte immunoglobulin (horse) (DB09312)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ATG 8 mg/kg with TAC + MMF + steroids (Group B)
Trial: 19641203
Drug: Vaccine group
RxNorm normalized name: MENINGOCOCCAL OLIGOSACCHARIDE VACCINE GROUP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vaccine group (10 subjects)
Trial: 9071476
Drug: Cyclic estrogen-gestagen
RxNorm normalized name: cyclic AMP
DrugBank: Cyclic adenosine monophosphate (DB02527)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclic estrogen-gestagen replacement therapy (ERT)
Trial: 8374882
Drug: 30 minutes
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 minutes of oral cryotherapy
Trial: 8374882
Drug: 60 minutes
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60 minutes of oral cryotherapy
Trial: 12654665
Drug: Daptomycin 4
RxNorm normalized name: Daptomycin
DrugBank: Daptomycin (DB00080)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Daptomycin 4 mg/kg
Trial: 22908174
Drug: Daptomycin 6
RxNorm normalized name: Daptomycin
DrugBank: Daptomycin (DB00080)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Daptomycin 6 mg/kg
Trial: 22908174
Drug: Daptomycin 8
RxNorm normalized name: Daptomycin
DrugBank: Daptomycin (DB00080)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Daptomycin 8 mg/kg
Trial: 27261989
Drug: Music listening
RxNorm normalized name: Listerine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Music listening (ML) program
Trial: 25076428
Drug: Meglumine antimoniate
RxNorm normalized name: meglumine antimoniate
DrugBank: Meglumine antimoniate (DB13732)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Meglumine antimoniate (MA) treatment
Trial: 20407903
Drug: Contrast-enhanced MRA
RxNorm normalized name: Contrased
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Contrast-enhanced MRA using Gd-DOTA (intravenous bolus 0.1 mmol/kg)
Trial: 16223398
Drug: Intravenous clonidine
RxNorm normalized name: Clonidine
DrugBank: Clonidine (DB00575)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous clonidine 1 microg/kg
Trial: 7030120
Drug: Disoprofol 1.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Disoprofol 1.2 mg/kg
Trial: 7030120
Drug: Disoprofol 3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Disoprofol 3 mg/kg
Trial: 7030120
Drug: Methohexitone 1
RxNorm normalized name: Methohexitone
DrugBank: Methohexital (DB00474)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Methohexitone 1 mg/kg
Trial: 7030120
Drug: Methohexitone 2
RxNorm normalized name: Methohexitone
DrugBank: Methohexital (DB00474)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Methohexitone 2 mg/kg
Trial: 28303758
Drug: 3 g
RxNorm normalized name: Molds 3 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 g n‐3 polyunsaturated fatty acids (PUFAs) per day
Trial: 28303758
Drug: 3 g
RxNorm normalized name: Molds 3 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 g olive oil per day (control)
Trial: 27089418
Drug: Ginger extract
RxNorm normalized name: ginger extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ginger extract (3g daily for 1 month)
Trial: 22515652
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy using maxacalcitol lotion (weekdays) and betamethasone butyrate propionate lotion (weekends) for 4 weeks
Trial: 22515652
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy using maxacalcitol lotion (weekdays) and betamethasone butyrate propionate lotion (weekends) for 8 weeks
Trial: 22515652
Drug: Monotherapy with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monotherapy with maxacalcitol lotion after combination therapy
Trial: 7886461
Drug: Conservative treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conservative treatment with a newly developed boot
Trial: 26371
Drug: Inhaled Isoprenaline
RxNorm normalized name: isoprenaline
DrugBank: Isoprenaline (DB01064)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Inhaled Isoprenaline (1,500 microgram)
Trial: 29222947
Drug: Guselkumab (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Guselkumab (10 mg)
Trial: 29222947
Drug: Guselkumab (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Guselkumab (30 mg)
Trial: 29222947
Drug: Guselkumab (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Guselkumab (100 mg)
Trial: 29222947
Drug: Guselkumab (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Guselkumab (300 mg)
Trial: 21409897
Drug: Single dose
RxNorm normalized name: Citrucel Single Dose Packets (Orange)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of prunes daily
Trial: 21409897
Drug: Double dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Double dose of prunes
Trial: 15979283
Drug: Total parenteral
RxNorm normalized name: TPN - total parenteral nutrition
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Total parenteral nutrition (group I)
Trial: 12826854
Drug: Morphine with
RxNorm normalized name: opium alkaloids with morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morphine with naloxone 0.8 mg
Trial: 12826854
Drug: Morphine alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morphine alone (placebo)
Trial: 8263895
Drug: Mailed prescription-refill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mailed prescription-refill reminders
Trial: 8263895
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of mailed reminders and unit-of-use packaging
Trial: 2938986
Drug: Bromocriptine treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bromocriptine treatment to control PRL levels during anesthesia
Trial: 2938986
Drug: No bromocriptine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No bromocriptine treatment
Trial: 30095660
Drug: Glycopyrrolate (0.005
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glycopyrrolate (0.005 mg/kg, intramuscular injection)
Trial: 30095660
Drug: Control (no
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (no glycopyrrolate administration)
Trial: 22048442
Drug: Discontinuation of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Discontinuation of ASA
Trial: 20720176
Drug: EX‐FED (beverage
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EX‐FED (beverage containing 5 kcal, 0.83 g carbohydrate, 0.37 g protein, and 0.03 g fat)
Trial: 18463425
Drug: Combined therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined therapy with levocabastine hydrochloride ophthalmic suspension and pemirolast potassium ophthalmic solution
Trial: 18463425
Drug: Single therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single therapy with levocabastine hydrochloride ophthalmic suspension
Trial: 16418140
Drug: Metoclopramide IV
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metoclopramide IV 0.5 mg 30 minutes before surgery
Trial: 16418140
Drug: Ondansetron IV
RxNorm normalized name: Ondansetron
DrugBank: Ondansetron (DB00904)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ondansetron IV 0.1 mg 30 minutes before surgery
Trial: 10390744
Drug: Nicardipine 20
RxNorm normalized name: nicardipine 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nicardipine 20 mg t.i.d. for one year
Trial: 1716546
Drug: 400 mg
RxNorm normalized name: mesna 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mg hydrocortisone per day
Trial: 1716546
Drug: 800 mg
RxNorm normalized name: bran 800 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 800 mg hydrocortisone per day
Trial: 6370437
Drug: Lorazepam (6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lorazepam (6 to 2 mg over 4 days)
Trial: 6370437
Drug: Chlordiazepoxide (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chlordiazepoxide (150 to 50 mg over 4 days)
Trial: 22677076
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of metformin (1000 mg twice daily) and pioglitazone (45 mg daily) for 3 months
Trial: 20673557
Drug: Atomoxetine and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atomoxetine and behavior therapy
Trial: 16344837
Drug: Mixed amphetamine
RxNorm normalized name: mixed amphetamine salts 5 MG Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mixed amphetamine salts extended release (MAS XR) 20-60 mg/day
Trial: 11122690
Drug: Baseline LDL-C
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Baseline LDL-C levels as low as 125 mg/dL
Trial: 7533484
Drug: Intravenous hydromorphone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous hydromorphone via PCA
Trial: 22168750
Drug: Silicone derivative
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Silicone derivative plus onion extract gel (Cybele(®) scagel)
Trial: 18633050
Drug: Levobupivacaine 0.2%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levobupivacaine 0.2% at 8 mL/h with 3-mL bolus and 15-min lockout (15-min lockout group)
Trial: 18633050
Drug: Levobupivacaine 0.2%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levobupivacaine 0.2% at 4 mL/h with 8-mL bolus and 30-min lockout (30-min lockout group)
Trial: 16170975
Drug: Tooth wipe
RxNorm normalized name: Vagisil Wipes
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tooth wipe (Oral‐B Brush‐Ups)
Trial: 3125307
Drug: Thyrotropin releasing
RxNorm normalized name: Thyrotropin releasing factor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thyrotropin releasing hormone analogue (RX77368)
Trial: 27028750
Drug: 3DP fast-melt
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3DP fast-melt formulation of levetiracetam
Trial: 27028750
Drug: Conventional immediate-release
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional immediate-release tablet of levetiracetam (Keppra(®))
Trial: 27028750
Drug: 3DP fast-melt
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3DP fast-melt formulation of levetiracetam under fed conditions
Trial: 24030782
Drug: Placebo (normal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (normal 0.9% saline infusion)
Trial: 14639068
Drug: Continuous renal
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous renal replacement therapies
Trial: 14639068
Drug: Daily dialysis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily dialysis
Trial: 14639068
Drug: Slow extended
RxNorm normalized name: Slow Sodium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Slow extended daily dialysis
Trial: 1287614
Drug: Cefaclor AF
RxNorm normalized name: Cefaclor
DrugBank: Cefaclor (DB00833)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cefaclor AF 500 mg twice daily
Trial: 1287614
Drug: Cefaclor 250
RxNorm normalized name: cefaclor 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefaclor 250 mg three times daily
Trial: 3891682
Drug: Proquazone 150
RxNorm normalized name: proquazone
DrugBank: Proquazone (DB13649)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Proquazone 150 mg
Trial: 3891682
Drug: Proquazone 75
RxNorm normalized name: proquazone
DrugBank: Proquazone (DB13649)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Proquazone 75 mg
Trial: 20220605
Drug: Gua-Sha therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gua-Sha therapy (scraping therapy)
Trial: 18560342
Drug: Phytoestrogens therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phytoestrogens therapy
Trial: 9890490
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of pentifylline (800 mg) and nicotinic acid (200 mg) daily
Trial: 9890490
Drug: Piracetam (2.4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Piracetam (2.4 g daily)
Trial: 7675959
Drug: 0.50 ml
RxNorm normalized name: witch hazel 0.50 mL in 1 mL TOPICAL SOLUTION [Medicated Pads]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.50 ml 95% USP alcohol/kg body weight
Trial: 7675959
Drug: 0.75 ml
RxNorm normalized name: ethanol 0.75 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.75 ml 95% USP alcohol/kg body weight
Trial: 7675959
Drug: 1.00 ml
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.00 ml 95% USP alcohol/kg body weight
Trial: 7675959
Drug: 0.135 ml
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.135 ml 95% USP alcohol/kg body weight (active placebo)
Trial: 92511
Drug: 700 CCA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 700 CCA units of purified subunit vaccine
Trial: 92511
Drug: 1,400 CCA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1,400 CCA units of whole-virus vaccine
Trial: 92511
Drug: 700 CCA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 700 CCA units of whole-virus vaccine
Trial: 26467994
Drug: QoL pathway
RxNorm normalized name: Immunoglobulin g1-lambda, anti-(human tissue factor pathway inhibitor (tfpi, extrinsic pathway inhibitor, epi, lipoprotein-associated coagulation inhibitor, laci))
FDA approved: no
EMA approved: no
PMDA approved: no
Description: QoL pathway intervention with tailored QoL diagnosis and therapy, including QoL profile and expert report with treatment recommendations.
Trial: 23406545
Drug: NK₁ receptor
RxNorm normalized name: Toll-like receptor 9
DrugBank: Toll-like receptor 9 (DB15320)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NK₁ receptor antagonist aprepitant
Trial: 14638493
Drug: All resiquimod
RxNorm normalized name: All Clear
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All resiquimod doses
Trial: 10651836
Drug: Hyperinsulinemic euglycemic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hyperinsulinemic euglycemic clamp with infusion of 20 glucose (30% enriched with 13C‐1‐glucose)
Trial: 10651836
Drug: Treatment with
RxNorm normalized name: Campho-Phenique Cold Sore Treatment with Drying Action
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment with troglitazone
Trial: 9079411
Drug: Recombinant follicle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Recombinant follicle stimulating hormone (rFSH; Puregon)
Trial: 6575025
Drug: Conventional APF
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional APF gel
Trial: 6575025
Drug: Thixotropic gel
RxNorm normalized name: Thyrotropic releasing hormone
DrugBank: Protirelin (DB09421)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Thixotropic gel
Trial: 6575025
Drug: Pluronic-based fluoride
RxNorm normalized name: Hydrogen fluoride
DrugBank: Hydrogen fluoride (DB11072)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pluronic-based fluoride gel
Trial: 28167467
Drug: Dermidoc cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dermidoc cream
Trial: 28167467
Drug: PolymixinB-bacitrin ointment
RxNorm normalized name: Bacitracin
DrugBank: Bacitracin (DB00626)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: PolymixinB-bacitrin ointment
Trial: 10955337
Drug: Health educational
RxNorm normalized name: Healthy Mama
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Health educational and exercise program (6 weekly sessions of 2 hours)
Trial: 1362205
Drug: Proglumide (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Proglumide (15 mg/day)
Trial: 2413282
Drug: Verapamil administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Verapamil administered orally (160 mg) before cytostatic treatment
Trial: 2413282
Drug: Verapamil administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Verapamil administered orally (160 mg) after cytostatic treatment